PROKARIUM
5.10.2021 10:02:04 CEST | Business Wire | Press release
Prokarium, a biopharmaceutical company pioneering the oncology field of microbial immunotherapy, today announced the appointment of Thomas Eldered as Chairman of the Board. Thomas Eldered succeeds Steve Chatfield, PhD, who will remain a Member of Prokarium’s Board of Directors.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20211005005314/en/
“Thomas brings to Prokarium over 30 years' leadership and executive experience in the biopharmaceutical industry, successfully leading biotech innovation from early-stage research through commercialization. Over the course of his career, he co-founded and managed Recipharm AB, growing it into one of the five largest CDMOs in the world. As President of Flerie Invest, he has invested in companies with ambitious science across the life science sector,” said Kristen Albright, PharmD, Chief Executive Officer of Prokarium. “We are thrilled to have the opportunity to work closely with Thomas during the next phase of Prokarium’s development.”
“I am honored to be joining Prokarium’s Board of Directors at this time,” Eldered said. “Prokarium has a compelling data set supporting the advancement of their lead microbial immunotherapy program and is aiming to shift the treatment paradigm for bladder cancer patients. The company is also developing an exciting next-generation Salmonella platform that will target a broad range of cancer indications as a monotherapy or in combination with other advanced immunotherapies.”
Eldered is President of Flerie Invest, which finances venture and growth stage companies engaged in drug development and associated tools or applications tackling major medical challenges. In 1995, Eldered co-founded Recipharm AB and went on to serve as CEO, leading the company through a successful IPO in 2014. Recipharm AB remains among the top five CDMOs in the world and now includes around 30 manufacturing and development facilities in Europe, India, Israel and North America. Eldered received his MSc in Industrial and Management Engineering at Linköping University.
About Prokarium
Prokarium is a biopharmaceutical company pioneering the field of microbial immunotherapy. Our pipeline is designed to unlock the next level of immuno-oncology by building on the most recent advances in cancer immunology. Prokarium’s lead program is focused on transforming the treatment paradigm in bladder cancer by orchestrating immune-driven, long-lasting antitumor effects. Prokarium is based London, UK. For further information, visit https://www.prokarium.com
.
View source version on businesswire.com: https://www.businesswire.com/news/home/20211005005314/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
DEWA International Launched as a Wholly Owned Independent Subsidiary of DEWA to Develop Global Energy and Water Projects9.7.2026 18:07:00 CEST | Press release
HH Sheikh Ahmed bin Saeed Al Maktoum, Chairman of the Dubai Supreme Council of Energy, announced the establishment of ‘DEWA International’, a wholly owned independent subsidiary of Dubai Electricity and Water Authority (DEWA). The company aims to develop conventional and clean energy projects worldwide and export Dubai’s successful energy and water infrastructure model to global markets. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260709099653/en/ DEWA International launched as a wholly owned independent subsidiary of DEWA to develop global energy and water projects (Photo: AETOSWire) HH Sheikh Ahmed bin Saeed Al Maktoum said: “Thanks to the vision and directives of His Highness Sheikh Mohammed bin Rashid Al Maktoum, Vice President and Prime Minister of the UAE and Ruler of Dubai, Dubai has become a global model for achievement and accelerated development. Through its world-class infrastructure, particularly in the energy
Echodyne Opens New Manufacturing Facility to Meet Surging Global Demand for Advanced MESA® Radar9.7.2026 15:00:00 CEST | Press release
New Washington State facility provides capacity to manufacture more than 30,000 radars annually, strengthening the U.S. defense industrial base As governments around the world accelerate investment in counter-unmanned aircraft systems (C-UAS) and short-range air defense, Echodyne today announced the opening of a new advanced radar manufacturing facility in Washington State, significantly expanding its manufacturing capacity to meet rapidly growing demand from U.S. and allied customers. With millions of drones manufactured and used by both sides in the Russian War in Ukraine, the need for enhanced safety for defense, national security, and critical infrastructure assets grows with every successful strike and interception. The low cost and high utility of drones dramatically alters the need for safety and security sensors. And as the low altitude economy takes off, hundreds of thousands of drones will perform a range of life-saving and commercial missions, requiring a sensor infrastructu
Orca Security Report: 99.9% of Fixable AI Vulnerabilities Remain Unpatched as AI Moves Into Production9.7.2026 15:00:00 CEST | Press release
Analysis of more than 1,200 production cloud environments provides a first-hand view into how organizations are embedding AI into business-critical workflows, exposing new security risks that traditional controls weren't built to address. Orca Security, a leader in cloud and AI security, today released its 2026 State of AI Security Report, offering a first-hand view into how AI is being deployed across more than 1,200 production cloud environments. The findings show AI is no longer limited to isolated pilots or developer experiments. Organizations are embedding AI into production applications, cloud services, and autonomous workflows faster than security programs can adapt. More than half (56%) of organizations have already deployed AI agents into production, while 51% use AI to build custom applications. At the same time, Orca found that 81% of organizations run vulnerable AI packages, and 99.9% of fixable AI vulnerabilities remain unpatched, highlighting how quickly AI has become ope
Viz.ai Expands into Neurodegenerative Disease with Cortechs.ai Collaboration9.7.2026 15:00:00 CEST | Press release
Cortechs.ai and Viz.ai partner to tackle multiple sclerosis and other neurodegenerative diseases across Viz.ai's health system network Viz.ai, the leader in AI-powered disease detection and intelligent care coordination, today announced a collaboration with Cortechs.ai, a global leader in neuroimaging and quantitative analysis solutions, to integrate Cortechs.ai's NeuroQuant and NeuroQuant MS suite into the Viz.ai platform, expanding access to quantitative neuroimaging for hospitals and health systems across the U.S. This partnership marks Viz.ai's expansion into neurodegenerative disease, growing Viz Neuro Suite beyond its already market-leading neuro offerings. The collaboration will begin with a focus on multiple sclerosis (MS), integrating quantitative MRI analysis from NeuroQuant MS directly into Viz.ai's care coordination workflow, giving clinicians both the quantitative precision and the coordination infrastructure needed to identify and manage MS patients at scale. “Viz.ai's co
SCP Standard Capital Partners AG: Fabian Becker Appointed Chairman of the Management Board and CEO9.7.2026 14:51:00 CEST | Press release
The Supervisory Board of SCP Standard Capital Partners AG (WKN: A12UPJ | ISIN: DE000A12UPJ7 | XETRA ticker: CAP) resolved today to appoint Mr. Fabian Becker as Chairman of the Management Board and Chief Executive Officer (CEO), effective as of 9 July 2026. Ms. Stephanie Schettler-Köhler will remain a member of the Management Board and will assume the role of Chief Operating Officer (COO). View source version on businesswire.com: https://www.businesswire.com/news/home/20260709982268/en/
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom